EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function

Inclusion Criteria:

• male or female patients aged 40 to 75 years with a viable graft
• patients who are recipients of a primary or secondary graft from a cadaveric expanded donor criteria
• patients who had no change of immunosuppressor two weeks prior to baseline
• patients who had no acute rejection four weeks prior to baseline
• patients who are willing and capable of giving written informed consent for study participation
• females of childbearing potential must have a negative serum pregnancy test within 7 days prior to baseline.Effective contraception must be used during the trial and for 6 weeks following discontinuation of the study medication, even where there has been a history of infertility
• Patients who are HCV and HBV negative

Exclusion Criteria

• patients who have a calculated GFR (Nankivell formula) of less than 30mL/min at baseline
• Patients who are recipients of multiple organ transplants
• Patients who are recipients of dual kidney transplants
• Patients with panel reactive antibodies >50% at transplant
• Patients with a known hypersensitivity to tacrolimus,EC-MPS or basiliximab at baseline
• Patients with a known malignancy or a history of malignancy, other than successfully treated non-metastatic basal or squamous cell carcinoma of the skin
• Patients who are HIV positive at study entry
• Patients who have received a kidney from a HCV positive or HBV positive donor
• Patients with signs of active immune process on graft biopsy at baseline
• Patients with polyoma (BK or JC)
• Patients with operative or technical failure

Exclusion Criteria:

-